...A. Our flagship drug is Jakafi. B. And in inflam, we started the commercialization activities with Opzelura, which was launched a couple of years ago for atopic dermatitis and vitiligo. C. On the commercial end with Jakafi and Opzelura, we continue to see strong growth in demand in both indications, even though the results of Q1 were a little bit masked by the Q1 typical dynamics, but the underlying fundamentals continue to be very strong. D. Also, we have been very busy this quarter bringing in additional assets. E. Two of the strategic transactions that we announced, the first one was around the program that we already own part of the rights, that is tafasitamab, we acquired the remaining rights to the program. F. The first indication for tafa is for relapse refractory [DLBCL] already launched under the name of [Monjuvi] in the U.S., Monjuvi ex-U.S., and 2 other indications are currently in development with data coming up this year and next year -- or actually this year, both later this...
